weight regain tirzepatide withdrawal leads to 25% in 82.5% of adults Tirzepatide for maintenance of bodyweight

Zepbound (tirzepatide) was FDA-approved in November 2023 for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with a weight-related condition

Peak plasma concentrations occur approximately 24-48 hours post-injection, with a half-life of approximately five days allowing for steady-state concentrations after four weeks

($1,349) as in Germany ($328.) The chart above shows list prices available through website searches for four weekly shots or a 30-day supply

They are now part of a broader medical discussion about obesity, insulin resistance, cardiovascular risk, fatty liver disease, inflammation, body composition, appetite signaling, and long-term metabolic health

Mechanism: Why Retatrutide Produces More Weight Loss Both drugs share two of three receptor targets